Uncategorized
FDA pilots AI-informed one-day facility inspections
Uncategorized
Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs
Alex Zevin, PhD
Director, Genomics Shared Resource
Fred Hutchinson Cancer Center
Panelist
Alex Zevin, PhD
Alex Zevin, PhD, began serving as the director of the Genomics Shared Resource at Fred Hutch in December 2022. Before that, he was a research scientist at ArcherDX where he developed NGS in vitro diagnostic devices including several clinical trial assays and an approved companion diagnostic. He also previously worked at InBios International and developed a rapid test for detection of anthrax.
Zevin has a bachelor’s degree in biochemistry from Colorado State University and a PhD in molecular biology from Arizona State University where he developed methods to characterize bacterial communities in engineered systems and conducted postdoctoral research at the University of Washington studying host-microbe interactions in non-human primate models.
- Time:
Digital PCR has emerged as a powerful approach for precise nucleic acid quantification, but it is constrained by limited dynamic range and the difficulty of multiplexing. Newer platforms, like Countable Labs’ single-molecule counting PCR, address both by offering precise quantification across a broad range of target abundances while simplifying multiplexing through single-molecule isolation and fluorescent imaging across millions of spatially fixed compartments.
In this GEN webinar, Alex Zevin, PhD, director of Fred Hutchinson Cancer Center’s Genomics Shared Resource, draws on hands-on experience with managing a suite of nucleic acid quantification technologies, including standard qPCR, digital droplet PCR, and Countable PCR, to share practical guidance for labs considering or expanding their PCR quantification capabilities. Key insights from the webinar include:
- How single-molecule counting differs from conventional digital PCR—and the sensitivity, precision, and multiplexing advantages it enables
- Real-world applications suited to single-molecule counting PCR, including validating NGS results, replacing or supplementing existing assays, and generating clinically actionable data
- Common challenges for converting qPCR and dPCR assays to single-molecule counting PCR, and how to overcome them
A live Q&A session will follow the presentations offering you a chance to pose questions to our expert panelist.
Produced with support from:
The post Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
On this week’s episode of “The Readout LOUD,” we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win for Cytokinetics, and FDA Commissioner Marty Makary’s White House troubles.
Oh, by the way, this is the 400th episode of your favorite biotech podcast.
On this week’s episode of “The Readout LOUD,” we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win for Cytokinetics, and FDA Commissioner Marty Makary’s White House troubles.
Oh, by the way, this is the 400th episode of your favorite biotech podcast.
Uncategorized
Science is becoming less disruptive. Is an aging workforce to blame?
Physicist Albert Einstein, widely regarded as one of the most prolific scientists of the past century, conducted much of his transformative work at the beginning of his career, before spending years defending his theories against the burgeoning field of quantum mechanics.
A new study shows that Einstein is not alone, and that most researchers begin their careers conducting their more disruptive work — overturning conventional wisdom and forging paths of their own — but as they age, they tend to abandon that groundbreaking energy. Instead, many become adept at connecting previously unlinked ideas. The paper, published Thursday in Science, helps offer an explanation of a trend that has increasingly worried scholars of science policy and innovation: that the pace of discovery has slowed in recent years.
Physicist Albert Einstein, widely regarded as one of the most prolific scientists of the past century, conducted much of his transformative work at the beginning of his career, before spending years defending his theories against the burgeoning field of quantum mechanics.
A new study shows that Einstein is not alone, and that most researchers begin their careers conducting their more disruptive work — overturning conventional wisdom and forging paths of their own — but as they age, they tend to abandon that groundbreaking energy. Instead, many become adept at connecting previously unlinked ideas. The paper, published Thursday in Science, helps offer an explanation of a trend that has increasingly worried scholars of science policy and innovation: that the pace of discovery has slowed in recent years.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
